Adlai Nortye Ltd. (NasdaqGM: ANL)
Health Care · Biotechnology · US
$15.06
+13.66% today · +636.5% 1Y
Adlai Nortye Ltd. (NasdaqGM: ANL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $530.00M and employs 109 people.
Over the last twelve months the share price has gained 636.5%, trading between 0.88 and 17.25.
Tweenvest scores Adlai Nortye Ltd. across four factors: quality 27/100, value 66/100. Its strongest factor is value.
ANL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $530.00M
- Revenue (TTM)
- $19.54M
- P/E
- —
- EPS
- -0.56
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- $17.25
- 52-week low
- $0.88
- Avg volume (3M)
- —
- Shares outstanding
- 40.00M
- Employees
- 109
- Next earnings
- —
About Adlai Nortye Ltd.
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
- ISIN
- US00704R1095
- Founded
- 2004
- Listed since
- Sep 29, 2023
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.